Our top pick for
Alector Inc is a biotechnology business based in the US. Alector shares (ALEC) are listed on the NASDAQ and all prices are listed in US Dollars. Alector employs 184 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$23.61|
|52-week range||$9.12 - $39.74|
|50-day moving average||$24.57|
|200-day moving average||$23.43|
|Wall St. target price||$44.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.68|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-2.52%|
|1 month (2021-09-20)||-8.38%|
|3 months (2021-07-23)||-27.95%|
|6 months (2021-04-23)||25.85%|
|1 year (2020-10-23)||148.79%|
|2 years (2019-10-23)||46.46%|
|3 years (2018-10-20)||N/A|
|5 years (2016-10-20)||N/A|
|Revenue TTM||$21.4 million|
|Gross profit TTM||$-135,771,000|
|Return on assets TTM||-27.63%|
|Return on equity TTM||-78.62%|
|Market capitalisation||$1.9 billion|
TTM: trailing 12 months
There are currently 7.5 million Alector shares held short by investors – that's known as Alector's "short interest". This figure is 10.7% up from 6.8 million last month.
There are a few different ways that this level of interest in shorting Alector shares can be evaluated.
Alector's "short interest ratio" (SIR) is the quantity of Alector shares currently shorted divided by the average quantity of Alector shares traded daily (recently around 857868.94977169). Alector's SIR currently stands at 8.76. In other words for every 100,000 Alector shares traded daily on the market, roughly 8760 shares are currently held short.
However Alector's short interest can also be evaluated against the total number of Alector shares, or, against the total number of tradable Alector shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alector's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Alector shares in existence, roughly 90 shares are currently held short) or 0.1412% of the tradable shares (for every 100,000 tradable Alector shares, roughly 141 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Alector.
Find out more about how you can short Alector stock.
We're not expecting Alector to pay a dividend over the next 12 months.
Over the last 12 months, Alector's shares have ranged in value from as little as $9.12 up to $39.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alector's is 1.1566. This would suggest that Alector's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Alector, Inc. , a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.